This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Skelaxin

Pfizer Inc.

Drug Names(s): metaxalone

Description: Metaxalone is an oral CNS depressant used as adjunct therapy for acute, painful musculoskeletal conditions. Although the drug is classified as a skeletal muscle relaxant, it does not directly relax skeletal muscle. The exact mechanism of action of metaxalone is unknown. Most of the beneficial effects of metaxalone are thought to be due to its sedative properties. Metaxalone does not effectively treat skeletal muscle hyperactivity secondary to chronic neurologic disorders (e.g., cerebral palsy).

Deal Structure: In January 2003, Elan Corporation agreed to sell its rights to Skelaxin and related rights to enhanced formulations of this product to King Pharmaceuticals.

In October 2010, Pfizer and King Pharmaceuticals announced that they have entered into a definitive merger agreement. In February 2011, Pfizer completed its acquisition of King.


Skelaxin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug